Research
Hormonal
For patients with Type 2 Diabetes and chronic kidney disease (CKD) or heart failure (HF), a sodium-glucose transporter protein-2 (SGLT-2) inhibitor with proven cardiovascular benefit is advised.
If you have Type 2 Diabetes along with kidney disease or heart failure, ask your doctor about SGLT-2 inhibitors. These medications are specifically advised because they have proven benefits for protecting your heart and kidneys.
WeakSupportsHIGH confidence
while for chronic kidney disease or heart failure, a sodium–glucose transporter proteins-2 inhibitor with proven benefit is advised.
Why this rating
Based on CVOTs and consensus grading.
Source
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
Alaaeldin Bashier et al. · Diabetology & Metabolic Syndrome · 2019
DOI 10.1186/s13098-019-0476-0
clinical_guidelineCited 64×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, including Medical Nutritional Therapy (MNT), are essential for maintaining the effectiveness of pharmacological therapies in managing T2DM and CVD.Limited
- For patients with type 2 diabetes and established cardiovascular disease, a combination of metformin and a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefits is recommended.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →